Efavirenz

Generic Name
Efavirenz
Brand Names
Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
Drug Type
Small Molecule
Chemical Formula
C14H9ClF3NO2
CAS Number
154598-52-4
Unique Ingredient Identifier
JE6H2O27P8
Background

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Indication

For use in combination treatment of HIV infection (AIDS)

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

First Posted Date
2005-07-12
Last Posted Date
2018-10-12
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
1864
Registration Number
NCT00118898
Locations
🇺🇸

Univ of Iowa Hosp and Clinic (1504), Iowa City, Iowa, United States

🇺🇸

Vanderbilt Therapeutics CRS (3652), Nashville, Tennessee, United States

🇺🇸

SUNY - Buffalo (Rochester) (1102), Buffalo, New York, United States

and more 49 locations

Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)

Phase 3
Completed
Conditions
HIV Infections
Tuberculosis
First Posted Date
2005-06-24
Last Posted Date
2011-12-22
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
70
Registration Number
NCT00115609
Locations
🇫🇷

Service des maladies Infectieuses et tropicales Hopital Necker-Enfants Malades, Paris, France

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

First Posted Date
2005-05-06
Last Posted Date
2014-06-25
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Target Recruit Count
368
Registration Number
NCT00110305

Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth

First Posted Date
2005-02-07
Last Posted Date
2021-11-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
377
Registration Number
NCT00102960

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

Not Applicable
Completed
Conditions
HIV Infections
Hepatitis C
First Posted Date
2005-01-04
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
2
Registration Number
NCT00100581
Locations
🇺🇸

Columbia Univ., HIV Prevention and Treatment Medical Ctr., New York, New York, United States

🇺🇸

Univ. of Texas Southwestern Med. Ctr., Amelia Court Continuity Clinic, Dallas, Texas, United States

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected People in Wenxi County, Shanxi Province, China

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2005-01-04
Last Posted Date
2011-02-23
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
100
Registration Number
NCT00100594

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal

Not Applicable
Completed
Conditions
HIV Infections
Interventions
Drug: Efavirenz
Drug: Lamivudine/zidovudine
First Posted Date
2005-01-04
Last Posted Date
2013-09-06
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
44
Registration Number
NCT00100568
Locations
🇸🇳

Centre National Hospitalier de Fann, Dakar CIPRA CRS, Dakar, Senegal

🇸🇳

Institut d'Hygiène Sociale, Dakar CIPRA CRS, Dakar, Senegal

Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings

Not Applicable
Completed
Conditions
HIV Infections
Tuberculosis
First Posted Date
2004-09-21
Last Posted Date
2010-03-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
592
Registration Number
NCT00091936
Locations
🇿🇦

King Edward VIII Hospital, Congella, Durban, South Africa

🇿🇦

Prince Cyril Zulu CDC, Congella, Durban, South Africa

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

First Posted Date
2004-06-08
Last Posted Date
2018-10-10
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
1571
Registration Number
NCT00084136
Locations
🇺🇸

University of Texas, Galveston, Galveston, Texas, United States

🇲🇼

College of Med. JHU CRS, P.O. Box 1131, Blantyre, Malawi

🇿🇼

UZ-Parirenyatwa CRS, AIDS Research Unit P.O. Box A178, Harare, Zimbabwe

and more 39 locations

Strategies for Delivering Anti-HIV Therapy in South Africa

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2004-04-07
Last Posted Date
2007-09-18
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
813
Registration Number
NCT00080522
Locations
🇿🇦

University of the Witwatersrand/Clinical HIV Research Unit, Johannesburg, Gauteng, South Africa

🇿🇦

University of Cape Town/Masiphumelele, Cape Town, South Peninsula, South Africa

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy